# Equator Therapeutics **Source:** https://geo.sig.ai/brands/equator-therapeutics **Vertical:** Healthcare **Subcategory:** General **Tier:** Emerging **Website:** equatortherapeutics.com **Last Updated:** 2026-04-14 ## Summary SF YC W20 biotech developing UCP1-activating thermogenesis drugs for obesity competing with GLP-1 agonists; seed-stage with proprietary HTS platform targeting brown fat calorie burning as next-generation anti-obesity mechanism. ## Company Overview Equator Therapeutics is a San Francisco-based early-stage biopharmaceutical company — backed by Y Combinator (W20) with seed funding from BioGenerator Ventures, Thoobik Holdings, Healthspan Capital, Endurance28, and Evolution VC Partners — developing first-in-class small molecule drugs that activate uncoupling protein 1 (UCP1) in brown and beige adipose tissue to increase metabolic rate and burn excess calories as heat, targeting obesity, metabolic syndrome, and related cardiometabolic diseases with a mechanism of action distinct from GLP-1 agonists (Ozempic, Wegovy) and traditional anti-obesity medications. Founded in 2019, Equator has developed a proprietary high-throughput drug discovery platform to identify selective UCP1 activators — compounds that safely activate the body's natural thermogenesis mechanism without the side effects (nausea, cardiovascular risk) that have limited previous metabolic drug programs. Equator Therapeutics' scientific hypothesis rests on the biology of brown adipose tissue (BAT): unlike white fat (which stores energy), brown fat burns energy to generate heat through uncoupling — the UCP1 protein acts as a proton leak channel in mitochondria, allowing cellular respiration to generate heat instead of ATP. Adult humans have measurable amounts of brown fat (primarily around the neck and clavicles) that can be pharmacologically activated. Cold exposure naturally activates UCP1 in brown fat (the scientific basis for cold plunge thermogenesis claims), but pharmacological UCP1 activation — targeting the protein with small molecule drugs that selectively bind and activate UCP1 without disrupting other mitochondrial function — could provide a continuous caloric burn increase of 100-300 calories/day. Equator's proprietary cell-based screening platform tests hundreds of thousands of compounds for selective UCP1 activation and mitochondrial safety, identifying lead candidates without the off-target mitochondrial toxicity that has failed previous thermogenic drug programs. In 2025, Equator Therapeutics competes in the obesity treatment, metabolic disease therapeutics, and brown fat/thermogenesis drug development space with Novo Nordisk (CSE: NOVO B, Ozempic/Wegovy GLP-1 franchise, $35B+ revenue), Eli Lilly (NYSE: LLY, Mounjaro/Zepbound GLP-1/GIP franchise, $45B+ revenue), and Morphic Therapeutic (NASDAQ: MORF, integrin-targeted metabolic drugs) for next-generation obesity pharmacotherapy investment and development. The GLP-1 revolution has validated the anti-obesity drug market at massive scale — Wegovy and Zepbound are blockbuster drugs with billions in sales — creating investor conviction in metabolic disease as a therapeutic category while establishing the clinical evidence bar that next-generation obesity drugs must meet (5-15%+ body weight reduction with acceptable safety profile). Equator's UCP1 mechanism offers complementary or additive combination potential with GLP-1 agonists (activating a thermogenesis pathway rather than satiety/glucose signaling). Y Combinator W20 backing provided early validation for the drug discovery platform approach. The 2025 strategy focuses on advancing lead UCP1 activator compounds through IND-enabling preclinical studies, seeking Series A financing from life sciences VCs with metabolic disease expertise, and building the safety pharmacology data package for regulatory submission. ## Frequently Asked Questions ### What is Equator Therapeutics? Equator Therapeutics is an early-stage biotech company founded in 2019 that develops novel drugs designed to burn calories and improve metabolism. The company targets the protein that mitochondria naturally use to produce heat, focusing on metabolic disease therapeutics and obesity treatment. ### What products and services does Equator Therapeutics offer? Equator Therapeutics develops metabolic disease therapeutics, including mitochondrial heat activation drugs, calorie-burning compounds, and obesity treatments. The company also operates a high-throughput drug screening platform to identify selective compounds without side effects. ### Who are the target customers for Equator Therapeutics? Based on their focus on metabolic disease therapeutics and obesity treatment development, Equator Therapeutics ultimately targets patients with metabolic disorders and obesity-related conditions. As an early-stage biotech company in preclinical development, their immediate focus is on drug development and pharmaceutical partnerships. ### When was Equator Therapeutics founded? Equator Therapeutics was founded in 2019. The company was accepted into Y Combinator's Winter 2020 (W20) batch. ### Where is Equator Therapeutics located? Equator Therapeutics is based in San Francisco, California. ### How much funding has Equator Therapeutics raised? Equator Therapeutics raised $125K in seed funding from investors including BioGenerator Ventures, Thoobik Holdings, Healthspan Capital, Endurance28, and Evolution VC Partners. The company was also backed by Y Combinator (W20). ### What stage of development is Equator Therapeutics at? Equator Therapeutics is an early-stage biotech company currently in preclinical development. They are focused on developing their drug discovery platform and identifying compounds that activate mitochondrial heat proteins. ### What technology does Equator Therapeutics use? Equator Therapeutics has developed a unique high-throughput drug discovery platform to identify compounds that selectively activate mitochondrial heat proteins. This technology targets the protein that mitochondria naturally use to produce heat without causing side effects. ### How can I contact or work with Equator Therapeutics? Equator Therapeutics is located in San Francisco, CA. Specific contact information is not provided in the available company information. ### What are the latest developments at Equator Therapeutics? Equator Therapeutics recently completed a $125K seed funding round with multiple investors including BioGenerator Ventures and Healthspan Capital. The company is actively developing drugs targeting mitochondrial heat protein and advancing its high-throughput drug discovery platform for metabolism and calorie-burning applications. ## Tags healthtech, saas, north-america, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*